Resilient Biotics is thrilled to announce the hiring of Dr. Jeffrey Meisner, PhD as Chief Science Officer. Dr. Meisner joins Resilient from Locus Biosciences where he was Director of Translational Medicine. Previously Dr. Meisner served as Associate Director of Biology at Kaleido Biosciences where he led multiple cross functional teams focused on microbiome therapeutic discovery in gut health indications.
“Jeff’s research background and management experience is exactly the right fit for Resilient Biotics as we enter the next stage of growth and expansion of our therapeutic development programs” said Dr. Chris Belnap, Resilient Biotics CEO. “Not only is Jeff an accomplished scientist, but he has also led cross-functional teams to bring microbiome products from the bench to the clinic.”
“I’m excited to join such a talented team at Resilient Biotics,” said Dr. Meisner. “We’ve seen some really promising advances with gut microbiome therapeutics in recent years, but the respiratory microbiome remains a largely untapped resource of potential therapies. The discovery platform at Resilient Biotics is uniquely positioned to leverage that potential and create a brand new class of products to combat respiratory diseases in livestock, as well as humans.”
Dr. Rachelle Galvin, President and COO, welcomed Jeff to Resilient Biotics’ RTP headquarters where he will be guiding the company’s respiratory microbiome programs. “I am thrilled to have Jeff join the leadership team at Resilient Biotics,” said Dr. Galvin. “He brings the scientific expertise and experience developing microbiome therapies that will accelerate the Resilient Biotics pipeline under his leadership.
